Edition:
United States

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

21.55USD
4:00pm EDT
Change (% chg)

$0.60 (+2.86%)
Prev Close
$20.95
Open
$21.00
Day's High
$21.60
Day's Low
$20.80
Volume
165,012
Avg. Vol
392,246
52-wk High
$27.16
52-wk Low
$7.80

Chart for

About

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $1,556.85
Shares Outstanding(Mil.): 74.31
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.91 16.25
EPS (TTM): -- -- --
ROI: -- 15.14 14.87
ROE: -- 16.37 13.89

BRIEF-Impax Laboratories Q2 GAAP loss per share $0.28

* Impax reports solid second quarter 2017 results with total revenues increasing 17% to $202 million

Aug 09 2017

BRIEF-Impax announces settlement of contract litigation on Opana ER CII extended-release tablets

* Impax announces settlement of contract litigation on Opana ER (oxymorphone hydrochloride) CII extended-release tablets

Aug 07 2017

BRIEF-Durect says ‍on July 24, Impax Laboratories terminated asset transfer and license agreement dated Jan. 3, 2014​

* Durect - ‍on July 24, Impax Laboratories provided notice to co, that Impax is terminating asset transfer and license agreement dated January 3, 2014​

Jul 28 2017

BRIEF-Impax reports FDA approval of its AB rated generic concerta extended-release tablets CII

* Impax announces FDA approval of its AB rated generic concerta® (methylphenidate hydrochloride) extended-release tablets CII

Jul 17 2017

BRIEF-Impax announces FDA approval, launch of additional strengths of generic Focalin XR extended-release capsules CII

* Impax announces FDA approval and launch of additional strengths of generic Focalin XR® (dexmethylphenidate hydrochloride) extended-release capsules CII

Jul 05 2017

BRIEF-Impax to review strategic alternatives for Taiwan manufacturing site

* Q1 revenue $184.4 million versus i/b/e/s view $191.2 million

May 10 2017

Merck cholesterol drug Vytorin faces competition from Impax, Teva generics

Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.

Apr 26 2017

UPDATE 1-Merck cholesterol drug Vytorin faces competition from Impax, Teva generics

April 26 Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.

Apr 26 2017

BRIEF-Impax announces FDA approval and launch of a generic version of vytorin

* Impax announces FDA approval and launch of a generic version of vytorin (ezetimibe/simvastatin tablets)

Apr 26 2017

Earnings vs. Estimates